New treatment approaches for premenstrual disorders

American Journal of Managed Care

Volumn 11, Issue SUPPL. 16, 2005, Pages

  Rapkin, Andrea J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CITALOPRAM; DANAZOL; DESIPRAMINE; DESOGESTREL PLUS ETHINYLESTRADIOL; DIURETIC AGENT; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FLUOXETINE; GONADORELIN ANTAGONIST; LEUPRORELIN; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PLACEBO; PYRIDOXINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANXIETY DISORDER; BREAKTHROUGH BLEEDING; BREAST TENDERNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOSE RESPONSE; DRUG RECEPTOR BINDING; FEMALE; HEADACHE; HUMAN; LIBIDO DISORDER; LIFESTYLE; NAUSEA; PATIENT COUNSELING; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; RELAXATION TRAINING; REVIEW; SEDATION; SIDE EFFECT; STRESS; VITAMIN SUPPLEMENTATION; WEIGHT GAIN;

COUNSELING; DIET; DRUG THERAPY; EMPATHY; FEMALE; HUMANS; LIFE STYLE; PREMENSTRUAL SYNDROME; STRESS, PSYCHOLOGICAL; UNITED STATES;

EID: 29844454952     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. ACOG Practice Bulletin, Premenstrual syndrome. Obstet Gynecol. 2000;95:end of issue 4.
2. Mortola JF, Girton L, Beck L, Yen SS. Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: the calendar of premenstrual experiences. Obstet Gynecol. 1990;76:302-307.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
4. Steege JF, Blumenthal JA. The effects of aerobic exercise on premenstrual symptoms in middle-aged women: a preliminary study. J Psychosom Res. 1993;37:127-133.
5. Ginsburg KA, Dinsay R. Premenstrual syndrome. In: Ransom SB, ed. Practical Strategies in Obstetrics and Gynecology. Philadelphia, Pa: WB Saunders Co; 2000:684-694.
6. Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol. 1998;179:444-452.
7. Johnson S. The multifaceted and widespread pathology of magnesium deficiency. Med Hypotheses. 2001;56: 163-170.
8. Walker AF, De Souza MC, Vickers MF, Abeyasekera S, Collins ML, Trinca LA. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J Womens Health. 1998;7:1157-1165.
9. Freeman EW, Stout AL, Endicott J, Spiers P. Treatment of premenstrual syndrome with a carbohydrate-rich beverage. Int J Gynaecol Obstet. 2002;77:253-254.
10. Wyatt KM, Dimmock PW, Jones PW, Shaughn O'Brien PM. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ. 1999;318:1375-1381.
11. Budeiri D, Li Wan Po A, Dornan JC. Is evening primrose oil of value in the treatment of premenstrual syndrome? Control Clin Trials. 1996;17:60-68.
12. Johnson SR. Premenstrual syndrome therapy. Clin Obstet Gynecol. 1998;41:405-421.
13. Preston JD, O'Neal JH, Talaga MC. Antidepressant medications. In: Handbook of Clinical Psychopharmacology for Therapists. 3rd ed. Oakland, Calif: New Harbinger Publications, Inc; 2002:163-180.
14. Physicians' Desk Reference, 58th ed. Montvale, NJ: Thomson PDR; 2004.
15. Sundström-Poromaa I, Bixo M, Bjorn I, Nordh O. Compliance to antidepressant drug therapy for treatment of premenstrual syndrome. J Psychosom Obstet Gynaecol. 2000;21:205-211.
16. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry. 1999;56:932-939.
17. Pearlstein TB, Stone AB, Lund SA, Scheft H, Zlotnick C, Brown WA. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol. 1997;17: 261-266.
18. Evans SM, Haney M, Levin FR, Foltin RW, Fischman MW. Mood and performance changes in women with premenstrual dysphoric disorder: acute effects of alprazolam. Neuropsychopharmacology. 1998;19:499-516.
19. Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab. 1991;72:252A-252F.
20. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998;338:209-216.
21. O'Brien PM, Abukhalil IE. Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase-only danazol. Am J Obstet Cynecol. 1999;180(1 pt 1):18-23.
22. Hahn PM, Van Vugt DA, Reid RL. A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology. 1995;20:193-209.
23. Danocrine® [package insert]. New York, NY: Sanofi-Synthelabo; 1996.
24. Vellacott ID, Shroff NE, Pearce MY, Stratford ME, Akbar FA. A double-blind, placebo-controlled evaluation of spironolactone in the premenstrual syndrome. Curr Med Res Opin. 1987;10:450-456.
25. Wang M, Hammarback S, Lindhe BA, Backstrom T. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand. 1995:74:803-808.
26. Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol. 2004;217:255-261.
27. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000;62:29-38.
28. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res. 1992;36:257-266.
29. Bäckström T, Hansson-Malmström Y, Lindhe BÅ, et al. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations. Contraception. 1992;46:253-268.
30. Joffe H, Cohen LS, Harlow BL. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol. 2003;189:1523-1530.
31. Yasmin®. Physicians' Desk Reference, 59th ed. Montvale, NJ: Thomson PDR; 2005:930-938.
32. Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Cend Based Med. 2001;10:561-569.
33. Apter D, Borsos A, Baumgartner W, et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care. 2003;8:37-51.
34. Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care. 2000;5:124-134.
35. Sangthawan M, Taneepanichskul S. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms. Contraception. 2005;71:1-7.
36. Borenstein J, Yu HT, Wade S, Chiou CF, Rapkin A. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. J Reprod Med. 2003;48:79-85.
37. Sillem M, Schneidereit R, Heithecker R, Mueck AO. Use of an oral contraceptive containing drospirenone in an extended regimen. Eur J Contracept Reprod Health Care. 2003;8:162-169.
38. Yonkers KA, Foegh ML. A new low-dose, drospirenone-containing oral contraceptive (OC) with a new dosing regimen is effective in reducing premenstrual dysphoric disorder (PMDD) [abstract]. Fertil Steril. 2004;82:O-255, S102-S103.
39. Yonkers KA, Brown C, Pearlstein TB, et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005;106:492-501.
40. Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA. 1997;278: 983-988.
41. Halbreich U, Bergeron R, Yonkers KA, Freeman E, Stout AL, Cohen L. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Cynecol. 2002;100:1219-1229.
42. Griswold D. Menstruation and related problems and concerns. In: Youngkin EQ, Davis MS. Women's Health: A Primary Care Clinical Guide. Upper Saddle River, NJ: Pearson Education, Inc; 2004:145-164.